Literature DB >> 28559994

MiR-144-3p inhibits cell proliferation and induces apoptosis in multiple myeloma by targeting c-Met.

Yue Zhao1, Zhongshi Xie2, Jie Lin1, Peng Liu3.   

Abstract

MicroRNA-144-3p (miR-144-3p) has been implicated in the development of many types of cancer. However, its role in multiple myeloma (MM) remains largely unknown. In this study, we found that miR-144-3p was downregulated in both MM cell lines and plasma from patients with MM. In vitro studies further showed that transfection of an miR-144-3p mimic into MM cells inhibited their proliferation and colony formation, and promoted cell cycle arrest at the G0/G1 phase and apoptosis. In addition, we found that miR-144-3p could directly target the 3'-untranslated region of cellular-mesenchymal to epithelial transition factor (c-MET) and suppress c-MET expression and its downstream signaling pathway (PI3K/AKT). Rescue experiments revealed that overexpression of c-MET partially reversed the inhibition effect of miR-144-3p in MM cells. In vivo studies confirmed that restoration of miR-144-3p suppressed tumor growth in xenograft nude mice by repressing c-MET. Overall, these findings demonstrate that miR-144-3p functions as a tumor suppressor in MM by targeting c-MET, suggesting that miR-144-3p might serve as a potential therapeutic target in MM.

Entities:  

Keywords:  MiR-144-3p; apoptosis; c-MET; multiple myeloma; proliferation

Year:  2017        PMID: 28559994      PMCID: PMC5446526     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  30 in total

Review 1.  Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma.

Authors:  Teru Hideshima; Paul G Richardson; Kenneth C Anderson
Journal:  Mol Cancer Ther       Date:  2011-11       Impact factor: 6.261

Review 2.  Treatment advances in multiple myeloma.

Authors:  Guido Tricot; Bart Barlogie; Frits Van Rhee
Journal:  Br J Haematol       Date:  2004-04       Impact factor: 6.998

Review 3.  The Met pathway: master switch and drug target in cancer progression.

Authors:  Massimiliano Mazzone; Paolo M Comoglio
Journal:  FASEB J       Date:  2006-08       Impact factor: 5.191

4.  MicroRNA-144-3p inhibits proliferation and induces apoptosis of human salivary adenoid carcinoma cells via targeting of mTOR.

Authors:  Fangyi Huo; Chen Zhang; Hong He; Yunlong Wang
Journal:  Biotechnol Lett       Date:  2015-12-19       Impact factor: 2.461

5.  MicroRNA-144 acts as a tumor suppressor by targeting Rho-associated coiled-coil containing protein kinase 1 in osteosarcoma cells.

Authors:  Jianjun Huang; Ying Shi; Hui Li; Meisongzhu Yang; Guohong Liu
Journal:  Mol Med Rep       Date:  2015-06-16       Impact factor: 2.952

Review 6.  Advances in biology and therapy of multiple myeloma.

Authors:  Sophie Barillé-Nion; Bart Barlogie; Régis Bataille; P Leif Bergsagel; Joshua Epstein; Robert G Fenton; Joth Jacobson; W Michael Kuehl; John Shaughnessy; Guido Tricot
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2003

7.  MicroRNA-144 mediates metabolic shift in ovarian cancer cells by directly targeting Glut1.

Authors:  Jia-Ying Fan; Yan Yang; Jing-Ying Xie; Yan-Ling Lu; Kun Shi; Yan-Qing Huang
Journal:  Tumour Biol       Date:  2015-12-11

8.  MicroRNA-138 inhibits proliferation of cervical cancer cells by targeting c-Met.

Authors:  B Li; X-X Yang; D Wang; H-K Ji
Journal:  Eur Rev Med Pharmacol Sci       Date:  2016       Impact factor: 3.507

Review 9.  miRNAs in human cancer.

Authors:  Thalia A Farazi; Jessica I Spitzer; Pavel Morozov; Thomas Tuschl
Journal:  J Pathol       Date:  2010-11-18       Impact factor: 7.996

Review 10.  Role of micro-RNAs in drug resistance of multiple myeloma.

Authors:  Jahangir Abdi; Hou Jian; Hong Chang
Journal:  Oncotarget       Date:  2016-09-13
View more
  26 in total

1.  Circulating microRNA-144-3p and miR-762 are novel biomarkers of Graves' disease.

Authors:  Qiuming Yao; Xuan Wang; Weiwei He; Zhenyu Song; Bin Wang; Jinan Zhang; Qiu Qin
Journal:  Endocrine       Date:  2019-04-04       Impact factor: 3.633

2.  Targeting of stromal versican by miR-144/199 inhibits multiple myeloma by downregulating FAK/STAT3 signalling.

Authors:  Nidhi Gupta; Raman Kumar; Tulika Seth; Bhavuk Garg; Alpana Sharma
Journal:  RNA Biol       Date:  2019-09-29       Impact factor: 4.652

3.  Inhibition of miR-144/199 promote myeloma pathogenesis via upregulation of versican and FAK/STAT3 signaling.

Authors:  Nidhi Gupta; Raman Kumar; Alpana Sharma
Journal:  Mol Cell Biochem       Date:  2021-03-01       Impact factor: 3.396

Review 4.  Identification of MicroRNAs With In Vivo Efficacy in Multiple Myeloma-related Xenograft Models.

Authors:  Ulrich H Weidle; Adam Nopora
Journal:  Cancer Genomics Proteomics       Date:  2020 Jul-Aug       Impact factor: 4.069

5.  MicroRNA-144 promotes remote limb ischemic preconditioning-mediated neuroprotection against ischemic stroke via PTEN/Akt pathway.

Authors:  Si-Jin Zhong; Miao-Miao Cui; Yu-Ting Gao; Xue-Yan Cao; Bin Chen; Xian-Ru Wen
Journal:  Acta Neurol Belg       Date:  2020-09-22       Impact factor: 2.396

6.  Overexpression of miR-101 promotes TRAIL-induced mitochondrial apoptosis in papillary thyroid carcinoma by targeting c-met and MCL-1.

Authors:  Jie Zhu; Zhenjie Li
Journal:  Oncotarget       Date:  2017-09-23

7.  miR‑144‑3p inhibits the proliferation, migration and angiogenesis of multiple myeloma cells by targeting myocyte enhancer factor 2A.

Authors:  Fei Tian; Huihan Wang; Huanxin Ma; Yuan Zhong; Aijun Liao
Journal:  Int J Mol Med       Date:  2020-07-06       Impact factor: 4.101

8.  Detrimental Role of miRNA-144-3p in Intracerebral Hemorrhage Induced Secondary Brain Injury is Mediated by Formyl Peptide Receptor 2 Downregulation Both In Vivo and In Vitro.

Authors:  Weijian Fan; Xiang Li; Dongping Zhang; Haiying Li; Haitao Shen; Yizhi Liu; Gang Chen
Journal:  Cell Transplant       Date:  2018-12-04       Impact factor: 4.064

9.  MicroRNA‑144‑3p may participate in the pathogenesis of preeclampsia by targeting Cox‑2.

Authors:  Suwei Hu; Jie Li; Ming Tong; Qian Li; Yong Chen; Hongmei Lu; Yixiong Wang; Lingfeng Min
Journal:  Mol Med Rep       Date:  2019-04-11       Impact factor: 2.952

10.  Circulating miRNAs as Auxiliary Diagnostic Biomarkers for Multiple Myeloma: A Systematic Review, Meta-Analysis, and Recommendations.

Authors:  Yunhui Xiang; Liuyun Zhang; Pinpin Xiang; Juan Zhang
Journal:  Front Oncol       Date:  2021-07-08       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.